Akademik Veri Yönetim Sistemi
Akdeniz Tıp Dergisi, cilt.10, sa.1, ss.131-136, 2024 (Hakemli Dergi)
Objective: Pazopanib is a multi-kinase inhibitor used in metastatic renal cell carcinoma or sarcomas (mRCC or mSTS). We aimed to investigate the relationship between pazopanib and macrocytosis and evaluate the clinical significance of this effect in mRCC or mSTS. Material and Methods: Patients diagnosed with mRCC and mSTS and have been treated with pazopanib were included. Drug-induced macrocytosis was defined as MCV >100 fL during any mount of treatment. ΔMCV was defined as difference between MCV during pazopanib treatment and baseline MCV. Data was collected retrospectively. Results: Fifty patients were included the study. During the pazopanib treatment, significant increase in MCV levels was observed and the mean MCV at the 0, 1, 3, 6, and 9 months were found as 86.7±7.6 fL, 87.8 ± 7.5, 92.4 ± 8.9, 94.8 ± 11.1 and 99.0 ± 10.7 fL, respectively (p<0.001). In the group with ΔMCV3 ≥ 5fL, median PFS was found as 48.0 months (95% CI, 26.3-69.9); in the group with ΔMCV3 <5, it was 25 months (95% CI, 14.6-35.4) (p:0.036). Median PFS was 21.0 months (%95 CI, 0-46.3) for macrocytic patients compared to 4.0 months (%95 CI, 2.0-5.9) in normocytic patients (p:0.023). There was no statistically significant difference between the groups for overall survival. Conclusion: A significant increase in MCV values or the development of macrocytosis during the pazopanib treatment in mRCC and mSTS, can be used as an important biomarker for progression-free survival.